Company Overview and News

0
DCM Shriram Limited - Updates

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Shareholders meeting

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Public Announcement - Buyback of Shares

2018-06-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Public Announcement - Buyback of Shares

2018-06-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Buyback

2018-06-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram rallies 8% after board approves share buyback up to Rs 250 cr

2018-06-18 moneycontrol
DCM Shriram informed exchanges that the board of directors have approved the buyback of fully paid up equity shares for up to Rs 250 crore and fixed the maximum price to buyback shares at Rs 450 per share.
DCMSHRIRAM 523367

83
Market Live: Nifty volatile, Auto index outperforms; Infosys, HDFC twins dip

2018-06-18 moneycontrol
Shriram Mutual Fund has revised the exit load structure of Shriram Equity and Debt Opportunities Fund with immediate effect, the fund house said in an addendum.
539150 ADANIENT 532617 532538 ICLQY 531349 PNCINFRA 512599 TTNQY 532343 532662 500470 532540 UCLQY CELG YESBANK INDIGO PANACEABIO CELGZ HINDALCO ANNRY TVSMOTOR IBN HTMEDIA JETAIRWAYS UCLQF 532648 YYBKY 532822 ULTRACEMCO 539448 HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 IDEA TCS DCMSHRIRAM 500440 523367

0
DCM Shriram Limited - Outcome of Board Meeting

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

0
DCM Shriram Limited - Buyback

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DCMSHRIRAM 523367

83
Market Live: Midcap underperforms Nifty; ICICI Bank top gainer on Sensex

2018-06-18 moneycontrol
Market sentiment was being dominated by trade tensions between the U.S. and China with new tariffs on the table. More than 800 Chinese goods are due to get an extra 25 percent tariff starting on July 6. As a result, China has responded with a 25 percent tariff that will also be applied to certain US products starting on the same day, reports CNBC.
539150 ADANIENT 532617 532538 ICLQY 531349 PNCINFRA 512599 TTNQY 532343 532662 500470 532540 UCLQY CELG YESBANK INDIGO PANACEABIO CELGZ HINDALCO ANNRY TVSMOTOR IBN HTMEDIA JETAIRWAYS UCLQF 532648 YYBKY 532822 ULTRACEMCO 539448 HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 IDEA TCS DCMSHRIRAM 500440 523367

27
Market Live: Midcap underperforms Nifty; HPCL, IOC gain over 5%; ICICI Bank up 3%

2018-06-18 moneycontrol
Buzzing: PNC Infratech share price fell nearly 4 percent after the UP government has decided to reinvite bids for Purvanchal Expressway and cancelled the company's Rs 1,738.44 crore offer made earlier.
539150 ADANIENT 532617 532538 ICLQY PNCINFRA 512599 TTNQY 532343 500470 532540 UCLQY YESBANK INDIGO HINDALCO ANNRY TVSMOTOR IBN JETAIRWAYS UCLQF 532648 YYBKY 532822 ULTRACEMCO 539448 HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 IDEA TCS DCMSHRIRAM 500440 523367

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...